- Home
- FAAS vs VYNE Comparison
FAAS vs VYNE Comparison
Compare FAAS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- VYNE
- Stock Information
- Founded
- FAAS 2021
- VYNE 2003
- Country
- FAAS Indonesia
- VYNE United States
- Employees
- FAAS N/A
- VYNE N/A
- Industry
- FAAS
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- FAAS
- VYNE Health Care
- Exchange
- FAAS NYSE
- VYNE Nasdaq
- Market Cap
- FAAS 34.6M
- VYNE 35.7M
- IPO Year
- FAAS N/A
- VYNE 2018
- Fundamental
- Price
- FAAS $0.58
- VYNE $2.74
- Analyst Decision
- FAAS
- VYNE Strong Buy
- Analyst Count
- FAAS 0
- VYNE 2
- Target Price
- FAAS N/A
- VYNE $6.88
- AVG Volume (30 Days)
- FAAS 366.1K
- VYNE 84.7K
- Earning Date
- FAAS 09-17-2024
- VYNE 02-27-2025
- Dividend Yield
- FAAS N/A
- VYNE N/A
- EPS Growth
- FAAS N/A
- VYNE N/A
- EPS
- FAAS N/A
- VYNE N/A
- Revenue
- FAAS $57,730,593.00
- VYNE $493,000.00
- Revenue This Year
- FAAS N/A
- VYNE $28.30
- Revenue Next Year
- FAAS N/A
- VYNE N/A
- P/E Ratio
- FAAS N/A
- VYNE N/A
- Revenue Growth
- FAAS 38.16
- VYNE 39.27
- 52 Week Low
- FAAS $0.38
- VYNE $1.57
- 52 Week High
- FAAS $12.97
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- FAAS 47.80
- VYNE 56.12
- Support Level
- FAAS $0.45
- VYNE $2.39
- Resistance Level
- FAAS $0.67
- VYNE $2.65
- Average True Range (ATR)
- FAAS 0.11
- VYNE 0.20
- MACD
- FAAS 0.01
- VYNE 0.05
- Stochastic Oscillator
- FAAS 35.65
- VYNE 71.01
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.